You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE

Average Pharmacy Cost for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB 00093-7704-56 0.52584 EACH 2025-01-22
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB 82009-0109-30 0.52584 EACH 2025-01-22
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB 69238-2092-03 7.22399 EACH 2025-01-22
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB 70710-1364-03 7.22399 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Emtricitabine-Tenofovir Disoproxil Fumarate (TDF/FTC)

Introduction to TDF/FTC

Emtricitabine-tenofovir disoproxil fumarate (TDF/FTC), commonly known by the brand name Truvada, is a crucial medication for HIV pre-exposure prophylaxis (PrEP) and treatment. This combination drug has been a cornerstone in the fight against HIV/AIDS, but its market dynamics are influenced by several factors including patent status, generic availability, and cost-effectiveness.

Current Market Status

Global HIV Drugs Market

The global HIV drugs market is substantial and growing, with a market size of $34.13 billion in 2023, projected to reach $58.24 billion by 2032 at a CAGR of 6.2%[2].

TDF/FTC Market Segment

TDF/FTC is a key player in this market, particularly in the combination HIV medicines segment, which is expected to dominate the market due to its effectiveness in managing HIV and related infections[2].

Patent Status and Generic Availability

TDF/FTC came off-patent in the US at the end of 2020, allowing for the introduction of generic versions. In countries where TDF/FTC is off-patent, generic versions have become significantly cheaper, costing between $210-$720 per year, depending on the supplier and government negotiations[1].

Price Projections

Branded vs. Generic Prices

The branded version of TDF/FTC, such as Truvada, costs around $16,600 per year. In contrast, generic TDF/FTC is expected to be much cheaper, potentially costing around $8,600 per year if priced at half the cost of the branded version. However, in more realistic scenarios where generic prices drop by 90% as seen in other countries, the cost could be as low as $1,660 per year[1].

Cost-Effectiveness Analysis

Studies have shown that even with optimistic assumptions about the benefits of the newer formulation Descovy (TAF/FTC) over TDF/FTC, the cost-effectiveness of Descovy is questionable. For instance, the maximum justifiable price for Descovy to be considered cost-effective is estimated to be around $1,970 per year, which is still significantly higher than the projected cost of generic TDF/FTC[1][4].

Impact of Government Spending and Research

Government Investment

The US government has invested substantially in the development of TDF/FTC for PrEP, with estimates suggesting spending between $143 million and $314 million in inflation-adjusted dollars[3].

Research and Development

Continuous research and development in HIV treatment, including the development of long-acting suppression antiretroviral therapy (ATLAS) and injectable formulations, are driving market growth. These innovations are expected to improve treatment compliance and outcomes, further solidifying the market position of TDF/FTC and its generic counterparts[2].

Market Trends and Challenges

Growing Demand

The increasing patient population and new product launches are fueling market growth. The Asia Pacific region, particularly countries like China and India, is expected to be the fastest-growing market due to large patient populations and increasing treatment programs[2].

Access and Awareness

Despite the growth, lack of access to treatment and unawareness of HIV infection status remain significant challenges. Government initiatives and private sector funding are crucial in addressing these issues and driving market expansion[2].

COVID-19 Impact

The COVID-19 pandemic had a temporary adverse impact on the HIV drugs market, including reduced sales volumes and disruptions in supply chains. However, with prescription volumes returning to pre-pandemic levels, the market is witnessing strong growth[2].

Competitive Landscape

The global HIV drugs market is dominated by key players such as ViiV Healthcare, Gilead Sciences, Janssen Pharmaceuticals, and Merck. These companies are driving market growth through new product launches, strategic collaborations, and public-private partnerships[2].

Regional Market Dynamics

North America

North America, particularly the US, has been a significant market for HIV drugs, with a market size of $24.09 billion in 2023. The region is expected to continue its dominance due to high awareness and easy availability of HIV/AIDS drugs[2].

Asia Pacific

The Asia Pacific region is anticipated to be the fastest-growing market, driven by highly populated countries like China and India, along with increasing treatment programs and funding from both the private sector and healthcare companies[2].

Key Takeaways

  • Generic Availability: The off-patent status of TDF/FTC has led to significantly cheaper generic versions, potentially costing between $210-$720 per year.
  • Cost-Effectiveness: Generic TDF/FTC is generally more cost-effective than branded alternatives like Descovy.
  • Market Growth: The global HIV drugs market is expected to grow substantially, driven by increasing patient populations, new product launches, and government initiatives.
  • Regional Dynamics: North America remains a dominant market, while the Asia Pacific region is expected to be the fastest-growing.
  • Challenges: Lack of access to treatment and unawareness of HIV infection status are significant challenges that need to be addressed.

FAQs

Q: What is the current cost of branded TDF/FTC in the US? A: The branded version of TDF/FTC, such as Truvada, costs around $16,600 per year[1].

Q: How much cheaper is generic TDF/FTC compared to the branded version? A: Generic TDF/FTC can be 90-95% cheaper than the branded version, costing between $210-$720 per year[1].

Q: What is the estimated government spending on TDF/FTC development? A: The US government spent between $143 million and $314 million in inflation-adjusted dollars on the development of TDF/FTC for PrEP[3].

Q: How is the COVID-19 pandemic impacting the HIV drugs market? A: The pandemic had a temporary adverse impact on the market, but with prescription volumes returning to pre-pandemic levels, the market is witnessing strong growth[2].

Q: Which region is expected to be the fastest-growing market for HIV drugs? A: The Asia Pacific region, particularly countries like China and India, is expected to be the fastest-growing market due to large patient populations and increasing treatment programs[2].

Sources

  1. AIDSmap: "Far fewer people would get PrEP in the US if generic TDF/FTC is replaced by Descovy TAF/FTC at current costs"
  2. Fortune Business Insights: "HIV Drugs Market Size & Growth | Global Report [2024-2032]"
  3. AJMC: "US Government Spent Far More on Costly HIV PrEP Development Than Previously Thought"
  4. Yale Medicine: "Expensive New Drug Could Undermine HIV Prevention Efforts"
  5. The Business Research Company: "HIV Drugs Global Market Report 2024"

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.